Atom Bioscience will use the capital from the series B round, which was co-led by Livzon Pharmaceutical, to advance its gout treatment into phase 2 trials.

Pharmaceutical company Livzon Pharmaceutical Group has co-led a $30m series B round for China-based metabolic disease drug developer Atom Bioscience with venture capital firm Sequoia Capital China.

The round also featured investment management firm Kaitai Capital and Shenzhen Dachen Caizhi Fortune VC, an investment platform owned by VC firm Fortune Capital.

Livzon paid approximately $10m for a 7.8% stake in Atom according to DealStreetAsia, which cited a stock exchange filing in January this year. It invested in the round through…

Robert Lavine

Robert Lavine is special features editor for Global Venturing.